Better Outcomes in Women With BRCA Mutations After Intraperitoneal Chemo

November 29, 2018

Pathogenic BRCA mutations are linked with better outcomes following intraperitoneal chemotherapy for high-grade ovarian cancer, according to a study published online in Gynecologic Oncology.

The study looked at 100 women with optimally resected high-grade ovarian cancer treated with adjuvant intraperitoneal chemotherapy between 2005 and 2016. Researchers compared outcomes among patients who tested positive for BRCA mutations and patients who tested negative or whose BRCA mutation status was unknown. Women were followed for a median 47 months.

Among the 77 women who received BRCA testing, 32% had BRCA mutations. In women with optimally resected ovarian cancer selected for intraperitoneal chemotherapy, pathogenic BRCA mutations were more common than expected, researchers observed.

Both median progression-free survival and median overall survival were longer in women with BRCA mutations compared with women with no or unknown BRCA mutations, the study found. Median overall survival was 110.4 months for the BRCA+ group compared with 67.1 months for the BRCA- group.

“This improvement is greater than has been reported for BRCA+ patients with IV chemotherapy,” researchers wrote. “The magnitude of this benefit suggests that patients with pathogenic mutations in BRCA may benefit from intraperitoneal therapy.”

Jolynn Tumolo

For articles by First Report Managed Care, click here

To view the First Report Managed Care print issue, click here